81results about How to "Low endotoxin content" patented technology

Water-soluble chitosan having a low concentration of endotoxin is disclosed. Products containing the water-soluble chitosan are also disclosed. Methods of making and using water-soluble chitosan having a low concentration of endotoxin are further disclosed.

The invention relates to a treatment method for purifying capsular polysaccharide, comprising the following steps of: (a), adding a lower alcohol with low final concentration into a cell capsular polysaccharide precipitate, and dissolving the capsular polysaccharide to form a mixed liquid; (b), carrying out solid-liquid separation on the mixed liquid and collecting a supernate; (c), adding a lower alcohol with high final concentration into the obtained supernate to form a rough precipitate containing the cell capsular polysaccharide; (d) adding the lower alcohol with the low final concentration into the rough precipitate so that the polysaccharide in the rough precipitate is in a dissolving state; (e) adding the lower alcohol with the high final concentration into the supernate so as to form the capsular polysaccharide precipitate; and (f) collecting the obtained capsular polysaccharide precipitate to obtain a purified cell capsular polysaccharide. The method conveniently, controllably and effectively improves recycling rates of the capsular polysaccharide and improves the security without using toxic reagents of phenol or chloroform.

The invention provides a soybean bioactive peptide additive used for cell medium, mass percentage of oligopeptide with molecular weight being less than 1000 Dalton in the soybean bioactive peptide additive accounts for more than 90% of total protein, the oligopeptide at least comprises one or more selected from YE, ERQ, QDPQ, EGGAH, PQGAR and AAGGSN. The soybean bioactive peptide additive used for cell medium enables complex formulation with a plurality of basic mediums, and can be used for serum-free culture on the a plurality of animal cells, cell medium cost is greatly reduced, pollution problem due to animal source component is reduced, cell proliferation is promoted, cell vitality is increased, and cell products expression is enhanced.

The invention discloses a membrane refining process for medicinal sodium chloride. The membrane refining process comprises the following steps: leading brine or crude salt water saturated by melting salt into a front reaction tank, adding barium chloride into the front reaction tank, filtering through a large-mesh filter after reaction, and removing sulfate radical through a first membrane filter; leading the sulfate radical-removed clear liquid into a rear reaction tank, adding sodium hydroxide and sodium carbonate into the rear reaction tank, and leading the solution into a second membrane filter after complete reaction so as to remove calcium and magnesium; leading the calcium and magnesium-removed clear liquid to an acid regulating tank, and adding hydrochloric acid to adjust the pH, so as to obtain refined salt water; producing the medicinal sodium chloride by an evaporation method, wherein the obtained medicinal sodium chloride has the advantages that the concentration of SS is less than or equal to 1mg/ L, the total concentration of Ca<2+> and Mg<2+> is less than or equal to 1 mg/L, and the concentration of SO4<2-> is less than or equal to 20 mg/L. According to the membrane refining process, a two-stage membrane filtration method is adopted, no flocculant is added, the process is continuous, the operation is simple, the treatment capacity is large, the pollution resistance is high, and the quality of the medicinal salt is obviously improved after evaporation and crystallization.

Method for isolating and purifying nucleic acids and/or oligonucleotides from a biological sample, the use of the isolated or purified nucleic acid and/or oligonucleotide for transfecting cells and also for the production of an agent for the treatment of genetic disorders, a composition suitable for the isolation or purification method and also the use of potassium acetate and a silica gel-like support material for isolating endotoxin-free nucleic acids and/or oligonucleotides or nucleic acids and/or oligonucleotides with reduced endotoxin content.

The invention discloses a fusion protein of human sperm albumin and human parathyroid hormone (1-34), and DNA sequence coding it as well as bacteria, yeast, animal cells and plant cells that carry the DNA sequence. It contains a first region with at least 85% sequence isogeny with human sperm albumin and a second region with at least 85% sequence isogeny with hPTH (1-34), and can substitute, delete or add several aminophenol residues on the premise of not changing its own property; there is a peptide linkage between the two regions; it not only retains the functional actions of hPTH (1-34) to activate receptor and stimulate bon reconstruction but also remarkably prolongs in vivo half life, and it is a medicinal protein that can cure osteoporosis.

The invention provides a method for removing endotoxin in protein. The method adopts a sequential combination of chromatography, ultrafiltration and common filtration, and accords with a protein purification process flow. With the method, protein purification is realized while endotoxin is effectively removed, and the properties of protein is not influenced. The method is especially suitable to be used in treating various genetically engineered bacteria expressed intracellular and extracellular proteins. With optimized designs of the conditions of filtering mode, filtering pressure, membrane pore size and the like, operation steps and operation time are simplified, such that production cost is reduced, and processing capacity is improved. With the method provided by the invention, the endotoxin content can be reduced to an animal clinical application standard range, and the properties of the product is not influenced while the endotoxin is removed. The method is suitable for large-scale productions and applications.

The invention discloses a meningitis vaccine and a preparation method thereof. The meningitis vaccine consists of polysaccharide obtained by fermenting A Neisseria meningitidis, polysaccharide obtained by fermenting C Neisseria meningitidis, polysaccharide obtained by fermenting Y Neisseria meningitidis, polysaccharide obtained by fermenting W135 Neisseria meningitidis, lactose and water. Experiments prove that the endotoxin content of the polysaccharide prepared by the method disclosed by the invention is very low and is 1 EU/mu g; the endotoxin content of the vaccine prepared by the polysaccharide is very low and is 1 EU/mu g. The vaccine disclosed by the invention is safe and effective; adverse reactions are smaller after the vaccine is inoculated; the vaccine can be accepted by receivers easily and is favorable to the popularization of national immunization policies.

The present disclosure is directed to processes for reducing the endotoxin level in gelatin and the resulting gelatin with low endotoxin content. The process includes dissolving a salt in a gelatin solution and filtering the gelatin-salt solution using anion exchange to reduce the endotoxin level. After reducing the endotoxin level of the gelatin-salt solution, the low endotoxin gelatin-salt solution is desalted to remove the salt, thereby producing a low endotoxin gelatin solution.

The invention provides a recombinant pig alpha-interferon as well as a preparation method and application thereof and belongs to the field of genetic engineering. The recombinant pig alpha-interferonhas high antiviral activity and can be effectively applied to prevention and control of viral infectious diseases of livestock and poultry. According to the technical scheme, the preparation method comprises the following steps: optimizing a pig alpha-interferon gene, optimizing an RNA (Ribonucleic Acid) secondary structure and eliminating certain common incision enzyme sites; then cloning to a pET-23b(+) carrier to transform escherichia coli and carrying out induced expression; after carrying out isolation denaturation and purification and renaturation on an inclusion body, obtaining the recombinant pig alpha-interferon. The recombinant pig alpha-interferon provided by the invention has very high valence and the antiviral activity can reach 10<10>U/mg; the recombinant sheep tau-interferoncan be effectively applied to prevention and treatment of viral diseases of the livestock and poultry.

The invention provides a method for optimally isolating monocytes in bovine peripheral blood. ACD-A is taken as an anticoagulant, the method comprises the optimization of centrifugal conditions, the optimization of cell cleaning conditions, the optimization of wall-sticking conditions and the like, and the success rate of the isolation is greatly improved. In the method, a whole set of complete system which comprises the sampling of bovine blood, the isolation of the monocytes in the bovine peripheral blood and the final transformation of the monocytes into macrophages is established for the first time, and the counting and dyeing are not required in the process, so that the time is saved and an isolation effect is improved. The survival rate of the monocytes isolated by the method is high; and the method is high in experimental repeatability and strong in operability, and provides powerful technical support for simply, conveniently and efficiently isolating the monocytes in the bovine peripheral blood.

The present invention provides a maize active peptide additive used for a cell culture medium, an oligopeptide of molecular weight less than 1000 daltons accounting for a mass percentage of ≥ 90% of the total protein in said maize active peptide additive, and said oligopeptide at least comprising one or more of AP, SAP, PAL, VNAP, PSSQ, and TQPGPQ. The maize active peptide additive of the present invention can be compounded with various basal media and can be used for various animal cell serum-free cultures.

The invention discloses a method for extracting albumin and globulin from bovine serum and a method for utilizing ox blood and relates to the technical field of protein extraction. According to the method for extracting albumin and globulin from bovine serum provided by the invention, the principle of plasma protein depositing in saline solution in a certain saturability is utilized, (NH4)2SO4 fractional precipitation is adopted and the bovine serum albumin is further purified. The bovine serum albumin is high in purity, is low in endotoxin content and meets the requirement of Chinese Biological Product Regulation. A saturated (NH4)2SO4 fractional repeated salting out method is utilized to extract the bovine serum albumin; the high molecular weight plasma protein is extremely removed; and the purity of the extracted bovine serum albumin is high. The method for extracting albumin and globulin from bovine serum provided by the invention is simple in process; no special device is required; the method is suitable for expanded production; and the method for utilizing ox blood provided by the invention can increase the use ratio of the ox blood.

The invention provides a method for preparing a quadruple inactivated vaccine by adopting VP2 protein of a bursal disease virus variant FJ19 (with the preservation number of CGMCC NO: 19381), and a corresponding vaccine. Antigens of the vaccine are a newcastle disease La Sota virus strain, an avian influenza TL18 strain (with the preservation number of CGMCC NO: 19382), a VP2 protein of a bursal disease virus variant FJ19 and an I group 8b type avian adenovirus Hexon protein. The quadruple inactivated vaccine disclosed by the invention is high in VP2 protein and Hexon protein content, high inimmunogenicity and low in formaldehyde and endotoxin content, has a relatively good protection effect on the currently popular variant bursal disease virus FJ19 and the group I 8b type avian adenovirus, is good in safety performance and definite in immune effect, can resist infection of Newcastle disease virus, avian influenza virus, variant bursal disease virus and group I 8b type avian adenovirus to clinical chicken flocks at the same time, is small in immune dose and long in duration, can reach the immune duration of 5 months under the condition of only 0.3 mL once, and at least provides aprotection rate of 70% for the chicken flocks.

The invention belongs to the field of a microbial fermentation technology (C12P) and a medicinal peptide (C07K), and particularly provides a fermentation preparation method of mannan peptide. According to the fermentation preparation method, vaccination, concentration and activated carbon treatment of hemolytic streptococcus and the like are improved, so that the endotoxin content of the prepared mannan peptide is significantly reduced and the safety of medication is improved. The invention further provides the mannan peptide as well as preparations and application thereof and the like.